Seraxis Holdings to Merge with Sernova Biotherapeutics

Xenetic Biosciences to Acquire Santersus AG

September 16, 2026

Medical Devices

Xenetic Biosciences entered into a definitive share exchange agreement to acquire all outstanding shares of Santersus AG in an all-stock transaction, subject to Xenetic stockholder approval and other customary closing conditions. The combination is intended to unite Santersus’ NucleoCapture blood-purification platform with Xenetic’s DNase technology and advance a broader pipeline targeting neutrophil extracellular traps across critical care, autoimmune disease, transplantation, and oncology.

Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

June 25, 2026

Biotechnology

Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

Neurocrine Biosciences to Acquire Celeno Therapeutics

April 7, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

April 6, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.

Korsana Biosciences Merges with Cyclerion Therapeutics

April 1, 2026

Biotechnology

Korsana Biosciences and Cyclerion Therapeutics entered into an all-stock merger agreement, with the combined company to operate as Korsana Biosciences and focus on advancing Korsana’s neurodegenerative disease pipeline. The merger was completed on September 8, 2026; a concurrent $380 million private placement was completed immediately before closing to fund operations and clinical milestones.

Veraxa Biotech Holding AG (merging into Veraxa Biotech AG) to be acquired by Voyager Acquisition Corp. in business combination with VERAXA Biotech AG

July 17, 2025

Biotechnology

VERAXA Biotech AG and Voyager Acquisition Corp. entered a business combination agreement in April 2025, which is structured as an absorption merger. In February 2026, VERAXA shareholders approved the merger and the issuance of new shares to Voyager as prerequisites to closing; trading of the combined company on NASDAQ under symbol “VRXA” is expected following Voyager’s shareholder approval.